Rogaine was not invented to grow hair. Upjohn developed minoxidil in the 1950s to treat ulcers - it failed. They pivoted to a blood pressure drug, approved as Loniten in 1979. During those trials, 60-80% of patients grew unexpected hair. A 1980 letter in the New England Journal of Medicine exposed the side effect. Upjohn launched Rogaine in 1988 - the first drug the FDA ever approved to regrow hair.

Rogaine Was Invented to Treat Blood Pressure

Posted 13 days agoUpdated 5 minutes ago

The green bottle in every drugstore wasn't designed to fix hair. It was designed to fix blood pressure - and even that wasn't the original plan.

An Ulcer Drug That Couldn't Cure Ulcers

In the late 1950s, chemists at Upjohn Company were searching for a new treatment for stomach ulcers. One compound they synthesized - later refined into minoxidil - showed promise in the lab. But when they tested it on animals, it did nothing for ulcers. What it did do was dramatically lower blood pressure by relaxing blood vessel walls. By 1963, Upjohn had developed minoxidil itself as a vasodilator: a drug that widens blood vessels and reduces hypertension.

The Side Effect Nobody Expected

The FDA approved oral minoxidil - sold as Loniten - in 1979 for patients with severe, drug-resistant high blood pressure. That's when doctors noticed something strange. In clinical trials, roughly 60 to 80 percent of patients taking Loniten reported growing new hair - on their faces, hands, and scalps. Upjohn's executives initially dismissed the phenomenon as a minor cosmetic nuisance and chose not to pursue it.

The Letter That Changed Everything

Upjohn's silence didn't last. In 1980, a physician named Zappacosta published a letter in the New England Journal of Medicine describing how a balding patient's hair had reversed while on minoxidil for hypertension. The letter was widely read. Upjohn realized that if they didn't develop a hair loss product, a competitor would. The company began clinical trials for a topical minoxidil solution - far lower dose, applied directly to the scalp to avoid blood pressure effects.

The FDA Blocked the Name "Regain"

Upjohn wanted to call the new product Regain. The FDA refused, ruling the name made an unacceptable promise - not every user would regrow hair. The company settled on Rogaine. On August 17, 1988, the FDA approved it as the first drug ever cleared specifically to treat male pattern baldness. It cost around $600 a year by prescription.

From Prescription to Pharmacy Shelf

In 1991, Rogaine received approval for women. By 1996, the FDA cleared over-the-counter sales, and the green bottle became a fixture of drugstore shelves worldwide. Today, minoxidil is still a blood pressure drug - and still a hair loss drug. The same molecule does both jobs. The only difference is how much you take and where you put it.

Enjoyed this? Get a new fact every day.

Follow FunFactz for the best ones in your feed.

or get one in your inbox

Frequently Asked Questions

What was Rogaine originally developed for?
Rogaine's active ingredient, minoxidil, was originally developed in the late 1950s by Upjohn Company to treat stomach ulcers. When that failed, it was repurposed as a blood pressure drug and approved as Loniten in 1979. The hair growth side effect was only discovered during those blood pressure trials.
How did they discover that minoxidil grows hair?
During clinical trials for Loniten (minoxidil for high blood pressure), researchers noticed that 60-80% of patients began growing unexpected hair on their faces and scalps. A 1980 letter in the New England Journal of Medicine by a physician named Zappacosta made this side effect public, forcing Upjohn to develop it as a hair loss treatment.
Why is Rogaine called Rogaine and not Regain?
Upjohn originally wanted to name the product Regain, but the FDA blocked the name because it implied the drug would restore hair for everyone. Since not all users see regrowth, the FDA considered the name misleading. The company settled on Rogaine as a compromise.
When was Rogaine approved by the FDA?
The FDA approved Rogaine on August 17, 1988, making it the first drug ever specifically approved to treat male pattern baldness. It was initially available by prescription only at around $600 per year. Over-the-counter sales were approved in 1996.
Does Rogaine still affect blood pressure?
Topical Rogaine uses a very low dose of minoxidil absorbed through the scalp, so the blood pressure effects are minimal for most users. Oral minoxidil, still prescribed for hypertension today, can lower blood pressure. The same molecule does both jobs - the difference is the dose and how it is applied.

Verified Fact

Verified Jun 19, 2026 · 5 sources checked

Source: The Pharmaceutical Journal
Show verification details

Verified 2026-06-19. 5 sources checked. Primary: Wikipedia (minoxidil article), Pharmaceutical Journal (pharma-j article), UPI Archives 1988, Your Health Magazine, Varona Hair Restoration. source_url CORRECTED from Pharmaceutical Journal to Wikipedia - PJ says research started in 1960 contradicting the facts 1950s framing; Wikipedia says late 1950s and covers all US-specific claims the PJ article omits. Claims checked: (1) 1950s origin: CONFIRMED - Wikipedia late 1950s, predecessor compound; minoxidil itself 1963 but article correctly frames this as later refinement. (2) Ulcers original purpose: CONFIRMED - Wikipedia explicit. (3) Loniten 1979 FDA: CONFIRMED multiple sources. (4) 60-80% hair growth in patients: CONFIRMED - Pharmaceutical Journal exact figure. (5) Zappacosta 1980 NEJM letter: CONFIRMED - Pharmaceutical Journal citation + search. (6) Rogaine 1988 first FDA hair drug: CONFIRMED - Duke Scholars, Wikipedia August 1988. (7) Aug 17 1988 exact date: CONFIRMED secondary sources. (8) Regain name rejected: CONFIRMED Wikipedia. (9) /year: CONFIRMED UPI Archives 1988 contemporary report. (10) 1991 womens approval: CONFIRMED Wikipedia. (11) 1996 OTC: CONFIRMED Wikipedia Feb 1996. (12) social_engagement_comment suppression claim: CONFIRMED Pharmaceutical Journal. Engine=2 acceptable (brand is protagonist, not trivia). prime_eligible=f correct (cs=15 < 17 threshold). No numeric coherence issues. No reversed agency. No invented precision. No corrections to content fields needed.

Related Topics

More from People & Mind

View all People & Mind